AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02385266
Drug: Placebo (for D-cycloserine)
RxNorm normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactose filled capsules to mimic DCS 200mg capsules
Trial: NCT01280292
Drug: Eltroxin
RxNorm normalized name: Eltroxin
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eltroxin dosage titration according to free T4 measurement every 3 months
Trial: NCT01367574
Drug: SC MNTX
RxNorm normalized name: MNTX
DrugBank: Methylnaltrexone (DB06800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose 1
Trial: NCT01367574
Drug: SC MNTX
RxNorm normalized name: MNTX
DrugBank: Methylnaltrexone (DB06800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose 2
Trial: NCT01367574
Drug: SC MNTX
RxNorm normalized name: MNTX
DrugBank: Methylnaltrexone (DB06800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose 3
Trial: NCT01941927
Drug: Trametinib (GSK1120212)
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib is a highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity.
Trial: NCT02648009
Drug: Gadolinium
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI with Gadolinium
Trial: NCT04345692
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet
Trial: NCT00834210
Drug: Dapsone
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
Trial: NCT00834210
Drug: Tazarotene
RxNorm normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
Trial: NCT02254044
Drug: bivatuzumab mertansine
RxNorm normalized name: Bivatuzumab
DrugBank: Bivatuzumab (DB06550)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04029428
Drug: 90Y-DOTATATE
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total activity of 90Y DOTATATE, 4x3.7GBq (14.8 GBq). Single session of i.v. infusion of 90Y DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
Trial: NCT04029428
Drug: (177Lu-DOTAOTyr3)Octreotate
RxNorm normalized name: 177Lu-DOTA-octreotate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total activity of 177Lu DOTATATE, 4x5.55GBq (22.2 GBq). Single session of i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
Trial: NCT04029428
Drug: 90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)
RxNorm normalized name: 177Lu-dotatate
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total activity of 90Y DOTATATE and 177Lu DOTATATE, 4x3.7GBq (14.8 GBq 50% each 90Y and 177Lu). Single session of i.v. infusion of 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
Trial: NCT00993863
Drug: ADL5859 30 mg
RxNorm normalized name: ADL5859
DrugBank: ADL5859 (DB05050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT00993863
Drug: ADL5859 100 mg
RxNorm normalized name: ADL5859
DrugBank: ADL5859 (DB05050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT00993863
Drug: ADL5859 200 mg
RxNorm normalized name: ADL5859
DrugBank: ADL5859 (DB05050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT00647244
Drug: Tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil 245 mg oral tablet once daily
Trial: NCT00647244
Drug: Abacavir
RxNorm normalized name: Abacavir
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abacavir 300 mg oral tablet twice daily
Trial: NCT00396786
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 5 mg once daily plus placebo enoxaparin syringe
Trial: NCT00396786
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 10 mg once daily plus placebo enoxaparin syringe
Trial: NCT00396786
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 20 mg once daily plus placebo enoxaparin syringe
Trial: NCT00396786
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 30 mg once daily plus placebo enoxaparin syringe
Trial: NCT00396786
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 40 mg once daily plus placebo enoxaparin syringe
Trial: NCT00396786
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg once daily plus Rivaroxaban placebo tablets
Trial: NCT00269750
Drug: OROS® oxybutynin or Ditropan®
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01510990
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gefitinib 250mg/day daily
Trial: NCT03265145
Drug: Stiolto Respimat
RxNorm normalized name: Stiolto Respimat 28 ACT
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration - 12 months
Trial: NCT03265145
Drug: ICS (Inhaled Corticosteroid) (Triple therapy)
RxNorm normalized name: Camphor Ice Topical Product
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duration - 12 months
Trial: NCT03265145
Drug: LABA (Long-Acting Beta Agonist) (Triple therapy)
RxNorm normalized name: Labafenogene marselecobac
DrugBank: Labafenogene marselecobac (DB17618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration - 12 months
Trial: NCT03265145
Drug: LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)
RxNorm normalized name: Lama palagi oil
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duration - 12 months
Trial: NCT03303053
Drug: Cholestyramine Powder 4g
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
Trial: NCT02670044
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cobimetinib will be administered orally as per schedule in Arm description.
Trial: NCT02670044
Drug: Idasanutlin
RxNorm normalized name: Idasanutlin
DrugBank: Idasanutlin (DB12325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idasanutlin will be administered orally as per schedule in Arm description.
Trial: NCT02670044
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax will be administered orally as per schedule in Arm description.
Trial: NCT02608268
Drug: MBG453
RxNorm normalized name: Anti-tim-3 monoclonal antibody mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).
Trial: NCT02608268
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: commercially available chemotherapy
Trial: NCT02917031
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg or 2.5 mg, plain, yellow, biconvex, round, film-coated tablet
Trial: NCT02917031
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg or 100 mg, gray capsule
Trial: NCT02917031
Drug: Placebo to match saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet
Trial: NCT02917031
Drug: Placebo to match sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg or 100 mg, gray capsule
Trial: NCT01821066
Drug: PD-0332991 alone
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PD-0332991 is administered alone as a single oral 125 mg dose on Day 1 of Period 1.
Trial: NCT01821066
Drug: Tamoxifen 60 mg
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On Days 1-4 of Period 2, tamoxifen is administered daily as 60 mg oral doses (using three 20mg tablets).
Trial: NCT01821066
Drug: Tamoxifen 20 mg
RxNorm normalized name: tamoxifen 20 MG
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On Days 5-27 of Period 2, tamoxifen is administered daily as 20 mg oral doses.
Trial: NCT01821066
Drug: PD-0332991 combination
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PD-0332991 is administered in combination with tamoxifen on Day 22 of Period 2 as a single 125 mg oral dose.
Trial: NCT00451958
Drug: Degarelix 80 mg / Degarelix 80 mg
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00451958
Drug: Degarelix 160 mg / Degarelix 160 mg
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00451958
Drug: Leuprolide 7.5 mg / Degarelix 80 mg
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00451958
Drug: Leuprolide 7.5 mg / Degarelix 160 mg
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03880045
Drug: vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy
Trial: NCT02533544
Drug: tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06090123
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.
Trial: NCT06090123
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10.
Trial: NCT04248712
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg tab twice daily by mouth for 12 week duration
Trial: NCT04248712
Drug: Loratadine
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg tab once daily by mouth for 12 week duration
Trial: NCT00632775
Drug: Hypotonic (0.45% NaCl/5% dextrose) IV maintenance fluids
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those \>20kg.
Trial: NCT00632775
Drug: Isotonic (0.9% NaCl/5% dextrose) IV maintenance fluids
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those \>20kg.
Trial: NCT03773666
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab is a monoclonal antibody (an antibody is a protein produced by the body's immune system) that works by blocking the Programmed Cell Death Ligand 1 (PD-L1), a protein on cancer cells that stops the body's immune system from killing cancer cells.
Trial: NCT03773666
Drug: Oleclumab
RxNorm normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oleclumab is a monoclonal antibody that works by reducing the amount of adenosine, a small molecule called a metabolite that binds to adenosine receptors on immune cells to regulate the immune system and suppress the immune response. Reducing the amount of immunosuppressive adenosine can increase the body's immune response to kill cancer cells.
Trial: NCT03120663
Drug: amoxicillin-clavulanic acid
RxNorm normalized name: amoxicillin / clavulanate
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During one dosing interval at steady state of the involved antimicrobials (ABs), AB plasma concentrations will be determined.~Besides, the measured creatinine clearance based on an 8-hour urinary collection (CrCl8h) will be used as the primary method for determining kidney function. Based on these values, CrCl8h will be calculated according to the standard formula and normalized to a body surface area (BSA) of 1.73m² .
Trial: NCT03545308
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose: 1 mg/kg
Trial: NCT02869126
Drug: 99mTc-Sestamibi
RxNorm normalized name: 99mTc-sestamibi
DrugBank: Technetium Tc-99m sestamibi (DB09161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First intravenous injection between 80 and 150 MBq according to patient weight and second injection with 3-time-higher activity, 2 hours after the first~For tomoscintigraphy
Trial: NCT02869126
Drug: Thallium-201
RxNorm normalized name: Thallium-201
DrugBank: Thallium Tl-201 (DB15361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of thallium-201 (50% activity of first 99mTc-Sestamibi injection)~For tomoscintigraphy
Trial: NCT01461499
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will start taking one a daily 150 mg/day of aliskiren. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of aliskiren will be given.In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
Trial: NCT01461499
Drug: any angiotensin receptor blockers
RxNorm normalized name: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The patient will start taking one a standard dose of an ARB in Japan. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of the ARB will be given. In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (DRI, another ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
Trial: NCT01520649
Drug: NSI-189 Phosphate
RxNorm normalized name: ethanol
DrugBank: NSI-189 (DB16230)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
Trial: NCT01520649
Drug: microcrystalline cellulose capsules
RxNorm normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
Trial: NCT00861757
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks
Trial: NCT00861757
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO, QD (30 min after meal) for 12 weeks
Trial: NCT03308968
Drug: Fremanezumab
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fremanezumab will be administered per dose and schedule specified in the arm.
Trial: NCT00164840
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03998514
Drug: CB4211 Dose TBD
RxNorm normalized name: TBD
DrugBank: 2,2-bis(4-hydroxy-3-tert-butylphenyl)propane (DB13008)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT04091932
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly usage of Pembrolizumab (2mg/kg weight) for 3 months.
Trial: NCT02681653
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin or placebo given for 7 days to patients of septic shock admitted to ICU
Trial: NCT00329823
Drug: Etanercept sc 50mg per week for 12 weeks
RxNorm normalized name: etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00219596
Drug: Xalacom
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00219596
Drug: unfixed Latanoprost and Timolol
RxNorm normalized name: latanoprost / timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01558115
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The dose of denosumab is 60 mg every 6 months by subcutaneous injection.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study
Trial: NCT04125329
Drug: Human umbilical cord mesenchymal stem cells
RxNorm normalized name: Human Umbilical Cord Mesenchymal Stem Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times
Trial: NCT00000277
Drug: Mazindol
RxNorm normalized name: Mazindol
DrugBank: Mazindol (DB00579)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02733822
Drug: Naloxone
RxNorm normalized name: Naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02735057
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03814356
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV MPH
Trial: NCT00603941
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
Trial: NCT01458548
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 IV on days 1, 8, 15 and 22.
Trial: NCT01458548
Drug: CHOP
RxNorm normalized name: cinchophen
DrugBank: Trichophyton mentagrophytes (DB10446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 750 mg/m2 IV, adriamycine 50 mg/m2 IV, vincristine 1.4mg/m2 IV, and prednisone 50mg/m2 PO every 3 weeks at days 50, 72, 94 and 116.
Trial: NCT00828958
Drug: Risperidone long-acting injectable
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00510445
Drug: Imetelstat Sodium (GRN163L)
RxNorm normalized name: Imetelstat
DrugBank: Imetelstat (DB14909)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose of GRN163L for this study will be 3.2 mg/kg. Subsequent dose levels will be 4.8, 6, 7.5, 9, 11, and 13.5 mg/kg. The maximum dose to be administered will not exceed 13.5 mg/kg.~Paclitaxel and carboplatin will be administered on Day 2 of each 21-day cycle.
Trial: NCT02180204
Drug: Tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenecteplase 0.25 mg/kg IV - Maximum 25 mg
Trial: NCT02180204
Drug: Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase 0.9 mg/kg IV - Maximum: 90 mg